• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Expert Ratings for Spectrum Pharma

    4/26/23 3:00:39 PM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPPI alert in real time by email

    Analysts have provided the following ratings for Spectrum Pharma (NASDAQ:SPPI) within the last quarter:

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 1 2 1 0 0
    Last 30D 0 0 0 0 0
    1M Ago 0 0 0 0 0
    2M Ago 0 0 0 0 0
    3M Ago 1 2 1 0 0

    According to 4 analyst offering 12-month price targets in the last 3 months, Spectrum Pharma has an average price target of $3.19 with a high of $4.00 and a low of $0.75.

    Below is a summary of how these 4 analysts rated Spectrum Pharma over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

    price target chart

    This current average has increased by 6.33% from the previous average price target of $3.00.

    Stay up to date on Spectrum Pharma analyst ratings.

    If you are interested in following small-cap stock news and performance you can start by tracking it here.

    Analyst Ratings: What Are They?

    Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

    Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $SPPI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPPI

    DatePrice TargetRatingAnalyst
    4/26/2023Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $SPPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Spectrum Pharma downgraded by JMP Securities

    JMP Securities downgraded Spectrum Pharma from Mkt Outperform to Mkt Perform

    4/26/23 6:26:55 AM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPPI
    SEC Filings

    View All

    SEC Form 15-12G filed by Spectrum Pharmaceuticals Inc.

    15-12G - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)

    11/9/23 5:00:17 PM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Spectrum Pharmaceuticals Inc.

    EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)

    9/28/23 12:15:18 AM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Spectrum Pharmaceuticals Inc.

    EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)

    9/28/23 12:15:20 AM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Bradrick Brittany returned 27,380 shares to the company, closing all direct ownership in the company

    4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)

    8/1/23 5:22:18 PM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Mcgahan Keith M returned 618,312 shares to the company, closing all direct ownership in the company

    4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)

    8/1/23 5:20:08 PM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Lim Juhyun returned 29,759 shares to the company, closing all direct ownership in the company

    4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)

    8/1/23 5:17:13 PM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

    Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology. Assertio intends to provide updated guidance for the combined business

    7/31/23 7:27:24 PM ET
    $ASRT
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals

    Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and

    7/27/23 4:01:00 PM ET
    $ASRT
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote "FOR" Proposed Transaction with Assertio Holdings, Inc.

    Recommendations from the Nation's Leading Independent Proxy Advisory Firms Recognize Value Creation Opportunity for Spectrum Stockholders and Strength of the Combined Company Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company") announced today that the leading independent proxy advisory firms, Institutional Shareholder Services, Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have each recommended that Spectrum stockholders vote "FOR" the proposal to adopt the Agreement and Plan of Merger ("Merger Agreement", and such proposal, the "Merger Proposal") at the upcoming special meeting of stockholders (the "Special Meeting") on July 27, 2023. Under the terms of the M

    7/20/23 7:00:00 AM ET
    $ASRT
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPPI
    Financials

    Live finance-specific insights

    View All

    Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction

    Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth across All Products Transaction Expected to Be Accretive to Assertio's Adjusted EPS and Operating Cash Flow in 2024 Spectrum Stockholders Will Receive Upfront Consideration of 0.1783 ASRT shares per SPPI Share ($1.14 per share) Plus One CVR for Total Potential Consideration of up to $1.34 per Share Upfront Consideration Represents a Premium of 65% and the Total Potential Consideration Repres

    4/25/23 6:00:00 AM ET
    $ASRT
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update

    -- First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection -- -- Q4 and full year net sales of $10.1 million -- -- Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Update First launch quarter for ROLVEDON, with net sales for the quarter and year ended December 31, 2022, totaling $10.1 million. Operating expenses decreased 45% year-over-year as the Company streamlined operation

    3/22/23 8:00:00 AM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

    Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Wednesday, March 22, 2023 @ 8:30 a.m. Eastern/5:30 a.m. Pacific To access the live call by phone, please go to this link (registration link) , and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live web

    3/17/23 7:00:00 AM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPPI
    Leadership Updates

    Live Leadership Updates

    View All

    Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

    Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology. Assertio intends to provide updated guidance for the combined business

    7/31/23 7:27:24 PM ET
    $ASRT
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022. Ms. Brennan has served on Spectrum's Board of Directors and as Chairperson of the Audit Committee since December 2020, and will relinquish her Board duties to assume this new role. "We are thrilled to have Ms. Brennan join Spectrum's senior leadership team as we progress our two late-stage assets toward commercialization," stated Tom Riga, CEO of Spectrum Pharmaceuticals. "Nora has been a strong board member and her experience as the audit committee chair will serve her well i

    5/11/22 7:00:00 AM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors

    Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years of finance, strategy and corporate development experience. "It's my pleasure to welcome Brittany to our Board of Directors at this important next stage in Spectrum's evolution," stated William Ashton, Chairman of the Board of Spectrum Pharmaceuticals. "As a seasoned executive in M&A and the life sciences sector, Brittany's experience and leadership will make an immediate impact on our board." "I am looking forward to joining Spectrum's Board at a

    5/5/22 7:00:00 AM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Spectrum Pharmaceuticals Inc. (Amendment)

    SC 13G/A - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)

    2/14/23 1:30:26 PM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Spectrum Pharmaceuticals Inc.

    SC 13G - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)

    2/10/22 4:05:14 PM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Spectrum Pharmaceuticals Inc.

    SC 13D - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)

    2/1/22 4:00:34 PM ET
    $SPPI
    Biotechnology: Pharmaceutical Preparations
    Health Care